← FDA DRUG APPROVALS

FDA ANDA · ANDA218987

LISDEXAMFETAMINE DIMESYLATE

Sponsor: GRANULES

APPLICATION
ANDA218987
TYPE
ANDA
ORIGINAL APPROVAL
2025-01-29
LATEST ACTION
2025-01-29
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

LISDEXAMFETAMINE DIMESYLATEPrescription
LISDEXAMFETAMINE DIMESYLATE 70MG · CAPSULE · ORAL
LISDEXAMFETAMINE DIMESYLATEPrescription
LISDEXAMFETAMINE DIMESYLATE 50MG · CAPSULE · ORAL
LISDEXAMFETAMINE DIMESYLATEPrescription
LISDEXAMFETAMINE DIMESYLATE 30MG · CAPSULE · ORAL
LISDEXAMFETAMINE DIMESYLATEPrescription
LISDEXAMFETAMINE DIMESYLATE 10MG · CAPSULE · ORAL
LISDEXAMFETAMINE DIMESYLATEPrescription
LISDEXAMFETAMINE DIMESYLATE 60MG · CAPSULE · ORAL
LISDEXAMFETAMINE DIMESYLATEPrescription
LISDEXAMFETAMINE DIMESYLATE 40MG · CAPSULE · ORAL
LISDEXAMFETAMINE DIMESYLATEPrescription
LISDEXAMFETAMINE DIMESYLATE 20MG · CAPSULE · ORAL

Approval history

2025-01-29UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →